Related Experiment Videos
Transgenic C. elegans as a model in Alzheimer's research
1Laboratory of cellular and Molecular Neuroscience, Department of Biological Sciences, The University of Southern Mississippi, Hattiesburg, MS 39406, USA.
Current Alzheimer Research
|June 28, 2005
Summary
Transgenic worms expressing amyloid-beta show Alzheimer's disease (AD) pathology, including paralysis and oxidative stress. This model aids in understanding AD mechanisms and testing new therapies.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Alzheimer's disease (AD) is linked to beta-amyloid peptide (Abeta) aggregation and brain cell death.
- Investigating AD pathology requires effective in vivo models to understand cellular mechanisms and develop therapies.
Purpose of the Study:
- To evaluate the utility of transgenic Caenorhabditis elegans (C. elegans) expressing human Abeta as a model for Alzheimer's disease.
- To explore the correlation between Abeta expression, oxidative stress, and neurodegeneration in a C. elegans model.
Main Methods:
- Utilized transgenic C. elegans expressing human Abeta.
- Observed phenotypes including progressive paralysis and amyloid deposits.
- Measured reactive oxygen species (ROS) and protein carbonyl levels.
- Conducted DNA microarray assays to identify gene expression changes.
Main Results:
- Transgenic C. elegans exhibited Abeta deposits and progressive paralysis, mimicking AD pathology.
- Increased levels of ROS and protein carbonyls were observed, consistent with AD oxidative stress.
- DNA microarray revealed upregulation of stress-related genes, including homologs of human alphaB-crystallin and tumor necrosis factor-related protein.
Conclusions:
- Transgenic C. elegans is a suitable in vivo model for studying Abeta-induced toxicity relevant to Alzheimer's disease.
- This model can be used to investigate the molecular mechanisms underlying AD pathology.
- The C. elegans model shows potential for pharmacological evaluation of novel therapeutic agents for AD.